Genomic atlas of Bifidobacterium infantis and B. longum informs infant probiotic design.
Shao Y, Wang S, Gichuki BM, Stares MD, Rozday TJ
Summary
0.5/10This is not a plant science article—it's microbiology research on infant gut bacteria. Researchers studied 4,000+ bacterial genomes and found that probiotic strains widely used in wealthy countries may not be optimal for infants in developing nations, where geographic variants of these bacteria are naturally dominant and adapted to local diets.
Key Findings
Global genomic atlas of 4,000+ Bifidobacterium genomes from 48 countries increased LMIC representation by 12-17 fold, enabling better regional strain selection
B. infantis dominates infant microbiota in low- and middle-income countries but is rarely detected in high-income countries, suggesting geographic adaptation
Bacterial strains show biogeographic stratification with predicted adaptations to plant-glycan-rich diets and breast-milk components, enabling precision probiotic design
Original Abstract
Bifidobacterium longum and B. infantis are pioneer colonizers of the neonatal gut and are widely used as probiotics to support infant growth, development, and disease resistance. However, commercial strains derived largely from high-income countries (HICs) may be suboptimal for infants in low- and middle-income countries (LMICs). We assembled a global genomic atlas of more than 4,000 genomes from 48 countries, increasing representation from LMICs by 12- to 17-fold. High-resolution phylogenomic and functional analyses support delineating B. longum and B. infantis as distinct species with divergent functions and epidemiological patterns. B. infantis dominates early-life microbiota in LMICs but is rarely detected in HICs. Natural B. infantis strains show extreme biogeographic stratification and predicted adaptations to local plant-glycan-rich diets and breast-milk-derived substrates, including urea and B vitamins. This genomic resource enables genome-guided selection of geographically matched strains to inform more effective probiotics and precision microbiome therapeutics for diverse infant populations.